দেশ: মাল্টা
ভাষা: ইংরেজি
সূত্র: Malta Medicines Authority
LENALIDOMIDE
Synthon BV Microweg 22, 6545 CM Nijmegen, Netherlands
L04AX04
LENALIDOMIDE 2.5 mg
HARD CAPSULE
LENALIDOMIDE 2.5 mg
POM
IMMUNOSUPPRESSANTS
Withdrawn
2018-11-06
Page 1 of 15 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LENALIDOMIDE SYNTHON 2.5 MG HARD CAPSULES LENALIDOMIDE SYNTHON 5 MG HARD CAPSULES LENALIDOMIDE SYNTHON 7.5 MG HARD CAPSULES LENALIDOMIDE SYNTHON 10 MG HARD CAPSULES LENALIDOMIDE SYNTHON 15 MG HARD CAPSULES LENALIDOMIDE SYNTHON 20 MG HARD CAPSULES LENALIDOMIDE SYNTHON 25 MG HARD CAPSULES lenalidomide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Lenalidomide Synthon is and what it is used for 2. What you need to know before you take Lenalidomide Synthon 3. How to take Lenalidomide Synthon 4. Possible side effects 5. How to store Lenalidomide Synthon 6. Contents of the pack and other information 1 WHAT LENALIDOMIDE SYNTHON IS AND WHAT IT IS USED FOR Lenalidomide Synthon contains the active substance ‘lenalidomide’. This medicine belongs to a group of medicines which affect how your immune system works. Lenalidomide Synthon is used in adults for • Multiple Myeloma • Myelodysplastic syndromes • Mantle cell lymphoma • Follicular lymphoma MULTIPLE MYELOMA Multiple myeloma is a type of cancer which affects a certain kind of white blood cell, called the plasma cell. These cells collect in the bone marrow and divide, becoming out of control. This can damage the bones and kidneys. Page 2 of 15 Multiple myeloma generally cannot be cured. However, the signs and symptoms can be greatly reduced or disappear for a period of time. This is called a ‘response’. Newly diagnosed multiple myeloma - in patients who have had a bone marrow trans সম্পূর্ণ নথি পড়ুন
Page 1 of 77 1. NAME OF THE MEDICINAL PRODUCT Lenalidomide Synthon 2.5 mg hard capsules Lenalidomide Synthon 5 mg hard capsules Lenalidomide Synthon 7.5 mg hard capsules Lenalidomide Synthon 10 mg hard capsules Lenalidomide Synthon 15 mg hard capsules Lenalidomide Synthon 20 mg hard capsules Lenalidomide Synthon 25 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 2.5 mg of lenalidomide. Each capsule contains 5 mg of lenalidomide. Each capsule contains 7.5 mg of lenalidomide. Each capsule contains 10 mg of lenalidomide. Each capsule contains 15 mg of lenalidomide. Each capsule contains 20 mg of lenalidomide. Each capsule contains 25 mg of lenalidomide. Excipient(s) with known effect: Each capsule contains 33.2 mg of lactose. Each capsule contains 66.4 mg of lactose. Each capsule contains 99.7 mg of lactose. Each capsule contains 132.9 mg of lactose. Each capsule contains 199.3 mg of lactose. Each capsule contains 265.8 mg of lactose. Each capsule contains 332.2 mg of lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule. Opaque white body and opaque green to light green cap, with a length of approximately14.3 mm, marked “L9NL” and “2.5”. Opaque white body and opaque white cap, with a length of approximately 18.0 mm, marked “L9NL” and “5”. Opaque white body and opaque yellow cap, with a length of approximately 18.0 mm, marked “L9NL” and “7.5”. Page 2 of 77 Opaque yellow body and opaque green to light green cap, with a length of approximately 21.7 mm, marked “L9NL” and “10”. Opaque white body and opaque blue to light blue cap, with a length of approximately 21.7 mm, marked “L9NL” and “15”. Opaque blue to light blue body and opaque green to light green cap, with a length of approximately 21.7 mm, marked “L9NL” and “20”. Opaque white body and opaque white cap, with a length of approximately 21.7 mm, marked “L9NL” and “25”. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Multiple myelom সম্পূর্ণ নথি পড়ুন